BioCentury

Rare disease patients held a mock funeral at FDA HQ. They are pressing for accelerated approval of MPS therapies -- and some are calling for Makary's exit. buff.ly/yEpkWoC

Recursion’s Khan: AI will be judged by the medicines it makes. Plus techbio's clearest near-term gains, its next frontier, and the case for precompetitive collaborations: The BioCentury Show buff.ly/pJnBvNg

In BioCentury's Venture Report: The week's fundings included rounds for Congruence, Crossbow, Mestag, Unnatural Products, R1 and Excalipoint buff.ly/QPAmLFI

Two cholesterol‑clearing drugs could fill different Niemann-Pick niches, shaped by age of onset and delivery route buff.ly/iUBDKyV

Newly FDA approved Icotyde from Protagonist and J&J will narrow the efficacy gap between oral and injectable therapies on the market. Will that be enough to drive patient demand? buff.ly/8B1iqCs

Beyond China, biotechs throughout Asia are finding deals with local and global partners, and the central theme is a high amount of diverse innovation, with first-in-class programs and a breadth of modalities. buff.ly/ALB9Mih

SBIR spigot reopened; $1B in non-dilutive funding to reach biotechs this year buff.ly/sVWPMhW

BioCentury's Science Spotlight includes evidence for moving KRAS inhibitors upstream to high-risk patients, engineered receptors to target low-CD70 solid tumors, Xaira’s virtual cell model, and more buff.ly/FiZUWTh

For Korea, there's no room for me-too's and me-betters. Rather, risky innovation is the safest option as Korea seeks to build its biotech footprint in the shadow of China buff.ly/tBywDOO

Clozel resumes CEO role at Idorsia, Mestag builds C-suite -- BioCentury's latest biopharma management moves buff.ly/Hoy4rYP

Cytomx’s expanded readout supports late-stage testing of masked EpCAM ADC. Plus: Nasus Pharma shares fall despite the superiority of NS002 over EpiPen, and more in BioCentury’s clinical report for Mar 11-17 buff.ly/hvR6yUm

Emerging Company Profile: Newly launched R1 Therapeutics has ex-Greater China rights to a therapy with a new mechanism for treating hyperphosphatemia in kidney disease patients buff.ly/FKsjOJR

Will geopolitics cool off a warming biotech financing environment?@StephenPHansen shares his insights on the latest #BioCenturyThisWeek podcast. Plus: Xenon's epilepsy data & the growing Friedreich ataxia pipeline — a BioCentury podcast buff.ly/rvVvhGL

BioCentury Deals Report: Spring Break? In BioCentury's Deals Report for Mar. 10-16: Of the few deals with disclosed financials, only two broke $100M in total value buff.ly/Zng4YYV

With more data, Structure’s oral obesity pill shows potential best-in-class efficacy. GLP-1R agonist aleniglipron delivers up to 16.3% placebo-adjusted weight loss at 44 weeks and will advance to Phase III. buff.ly/6pYCOan

.@US_FDA Commissioner Makary has testified to Congress once since his confirmation. Gottlieb testified 15 times in his 1st year, Califf at least 5. buff.ly/0ETALNl

After Friedreich ataxia's first approval, other therapies trying to patch mitochondria have stumbled. The second wave strives to fix the causative gene itself, FXN. buff.ly/v4Xg2ld

Korea rising: Takeaways from the BioCentury-BayHelix East-West Summit in Seoul — a BioCentury Podcast buff.ly/9yfLNKw

In BioCentury's Finance Report: Xenon and Dianthus raised nearly $1.5B in a pair of follow-ons that followed auspicious data readouts this week; two more biotechs drew $1B in convertible note offerings; and more buff.ly/NPfBJpY

Kenai: Off-the-shelf Parkinson’s progenitors with precision transplant tech. Allogeneic cell therapy newco brings precision brain delivery, functional imaging and ambitions beyond motor symptom control buff.ly/Y2Nbepw